This study pooled data from six randomized controlled trials to compare itraconazole and fluconazole in the per os treatment of acute vaginal and vulvovaginal candidiasis. The authors sought to compare itraconazole and fluconazole with respect to the in vivo and in vitro efficacy and safety of each drug. The six studies in the meta-analysis included 1092 enrolled non-pregnant patients with microscopically or microbiologically culture confirmed vaginal/vulvovaginal candidiasis. The results of the meta-analysis showed no difference between the two drugs in every comparison studied, including clinical cure and improvement at both the first follow-up visit (pooled odds ratio [OR] 0.94, 95% confidence interval [CI] 0.6–1.48) and second follow-up visit (OR 1.09, 95% CI 0.68–1.75), mycologic cure at the first and second follow-ups (OR 0.73, 95% CI 0.31–1.7 and OR 0.71, 95% CI 0.49–1.03, respectively), withdrawal of patients secondary to severe adverse events, and adverse events affecting the nervous and digestive systems. The authors concluded that both fluconazole and itraconazole can be used for efficacious and safe treatment of uncomplicated vaginal/vulvovaginal candidiasis.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Emergency Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.